Apixaban dose reduction to 2.5 mg twice daily appeared safe after 6 months of full-dose treatment for venous thromboembolism among patients with cancer, according to a study published in Journal of Thrombosis and Haemostasis.
Incidence rates of recurrent VTE and major bleeding both remained low after 12 months, results of the 30-month follow-up from the single-arm, interventional clinical trial showed.
“Reducing the dose of apixaban (Eliquis; Bristol Myers Squibb, Pfizer) to 2.5 mg twice daily after 6 months of 5 mg twice daily is not dangerous in [patients with cancer and VTE]. We cannot